VIVOBIOT
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
India's Vivo Bio Tech gains after getting 107.5 mln-rupee contract
** Shares of Vivo Bio Tech VIVO.BO rise 11.8% to 41.66 rupees
** Drug development and discovery services provider secures pre-clinical testing contract worth 107.5 mln rupees ($1.2 mln) for a novel molecule
** Contract includes toxicity studies across multiple endpoints, assessing genetic safety, environmental risk assessment, and analytical services
** Trading vols at 213,150 shares so far, over 4x the 30-day average
** Stock up ~12% YTD
($1 = 87.0800 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Vivo Bio Tech VIVO.BO rise 11.8% to 41.66 rupees
** Drug development and discovery services provider secures pre-clinical testing contract worth 107.5 mln rupees ($1.2 mln) for a novel molecule
** Contract includes toxicity studies across multiple endpoints, assessing genetic safety, environmental risk assessment, and analytical services
** Trading vols at 213,150 shares so far, over 4x the 30-day average
** Stock up ~12% YTD
($1 = 87.0800 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
Vivo Bio Tech Launches Large Animal Facility, Operations Already Commenced
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Jan 13 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
LAUNCHES LARGE ANIMAL FACILITY, OPERATIONS ALREADY COMMENCED
Source text: ID:nBSE21BrNV
Further company coverage: VIVO.BO
(([email protected];;))
Vivo Bio Tech Approves Fund Raising
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
BOARD APPROVES FUND RAISING VIA PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS
TOTAL ISSUE VALUE AGGREGATES UP TO 450 MILLION RUPEES
Source text: ID:nBSEbMVyzR
Further company coverage: VIVO.BO
(([email protected];;))
Jan 9 (Reuters) - Vivo Bio Tech Ltd VIVO.BO:
BOARD APPROVES FUND RAISING VIA PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS
TOTAL ISSUE VALUE AGGREGATES UP TO 450 MILLION RUPEES
Source text: ID:nBSEbMVyzR
Further company coverage: VIVO.BO
(([email protected];;))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Vivo Bio Tech do?
Vivo Bio Tech Ltd is a contract research company specializing in biotechnology and pharmaceutical drug discovery services. They offer a comprehensive range of services including insilico design, wet lab research, preclinical studies, and clinical trials.
Who are the competitors of Vivo Bio Tech?
Vivo Bio Tech major competitors are Jeevan Scientific, Zenotech Laboratorie, Dishman Carbogen Amc, Sun Pharma Adv. Res, Syngene Internation., Hikal, Suven Life Sciences. Market Cap of Vivo Bio Tech is ₹72 Crs. While the median market cap of its peers are ₹3,892 Crs.
Is Vivo Bio Tech financially stable compared to its competitors?
Vivo Bio Tech seems to be less financially stable compared to its competitors. Altman Z score of Vivo Bio Tech is 1.78 and is ranked 6 out of its 8 competitors.
Does Vivo Bio Tech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Vivo Bio Tech latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Vivo Bio Tech allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress
How strong is Vivo Bio Tech balance sheet?
Vivo Bio Tech balance sheet is weak and might have solvency issues
Is the profitablity of Vivo Bio Tech improving?
The profit is oscillating. The profit of Vivo Bio Tech is ₹4.09 Crs for TTM, ₹7.28 Crs for Mar 2025 and ₹2.53 Crs for Mar 2024.
Is the debt of Vivo Bio Tech increasing or decreasing?
Yes, The net debt of Vivo Bio Tech is increasing. Latest net debt of Vivo Bio Tech is ₹55.2 Crs as of Sep-25. This is greater than Mar-25 when it was ₹51.71 Crs.
Is Vivo Bio Tech stock expensive?
Vivo Bio Tech is not expensive. Latest PE of Vivo Bio Tech is 17.52, while 3 year average PE is 18.88. Also latest EV/EBITDA of Vivo Bio Tech is 5.93 while 3yr average is 6.31.
Has the share price of Vivo Bio Tech grown faster than its competition?
Vivo Bio Tech has given lower returns compared to its competitors. Vivo Bio Tech has grown at ~-4.86% over the last 8yrs while peers have grown at a median rate of -0.45%
Is the promoter bullish about Vivo Bio Tech?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Vivo Bio Tech is 35.16% and last quarter promoter holding is 36.43%
Are mutual funds buying/selling Vivo Bio Tech?
There is Insufficient data to gauge this.
